XXXX in survivors of cervical, endometrial, and ovarian cancers: The Cooper Center Longitudinal Study.

@entity1 @entity410 @entity5
BACKGROUND: @entity410 (CRF), a strong predictor of mortality, is impaired among cancer @entity1 . There is limited data, however, regarding CRF levels in @entity1 diagnosed with @entity5 . METHODS: We compared CRF among ovarian, endometrial, and cervical cancer cases (n=89) to age-matched controls (n=89) in the Cooper Center Longitudinal Study (CCLS). CRF was evaluated by a maximal treadmill exercise tolerance test using a modified-Balke protocol. Conditional logistic regression was used to test for case-control differences in @entity410 , after controlling for age and body mass index, and adhering to the matched pairs design. RESULTS: The mean ages of cancer cases and controls were 50.9 years and 51.1 years, respectively (p=0.81). Peak METs (1 MET=3.5 mL kg(-1)min(-1)) were 9.2    2.0 in cancer cases compared to 10.0    2.2 in controls (p=0.03). When stratifying by type of cancer, peak METs were 8.9    2.2, 8.4    1.9, 9.5    2.0 for @entity1 with ovarian, endometrial, and cervical cancer, respectively. A gynecological cancer diagnosis was associated with greater odds of having 1-MET lower CRF compared to controls (OR 1.31, 95% CI: 1.05-1.64, p=0.018), after controlling for age and BMI. CONCLUSION: Gynecologic cancer survivors were more likely to have a 1-MET lower CRF than controls. Given a 1-MET change in CRF is associated with a significant, we advocate for more robust research regarding CRF in gynecologic cancer @entity1 .
